Science

May 2, 2025, 18:25

LOXHD1 Identified as Immunotherapy Target in Ewing Sarcoma – Parker Institute for Cancer Immunotherapy

Parker Institute for Cancer Immunotherapy shared a post on X:

“Few cancers rob young lives of time like Ewing sarcoma. New Scientific Reports research led by PICI Investigator Beatriz Carreno, PhD (Penn Medicine), with contributions from Gerald P. Linette, MD, PhD, and Carl June, MD, reveals LOXHD1 as a tumor-specific target for immunotherapy. Supported by Parker Institute for Cancer Immunotherapy.”

Title: LOXHD1 is an oncofusion-regulated antigen of Ewing sarcoma

Authors: Tatiana Blanchard, Pouya Faridi, Chong Xu, Adham S. Bear, Reyaz ur Rasool, Grace Huang, Terry C. C. Lim, Rochelle Ayala, Khatuna Gabunia, Mei Ji, Avery D. Posey Jr, John Scholler, Irfan A. Asangani, Anthony W. Purcell, Gerald P. Linette, Carl H. June and Beatriz M. Carreno.

LOXHD1 Identified as Immunotherapy Target in Ewing Sarcoma - Parker Institute for Cancer Immunotherapy

You can read the Full Article on Scientific Reports.

Read about Ewing Sarcoma on OncoDaily.

LOXHD1 Identified as Immunotherapy Target in Ewing Sarcoma - Parker Institute for Cancer Immunotherapy

More posts featuring Parker Institute for Cancer Immunotherapy.

Adham S. Bear Anthony W. Purcell Avery D. Posey Jr Beatriz M. Carreno cancer Carl H. June Carl June Chong Xu Ewing sarcoma Gerald P. Linette Grace Huang immunotherapy Irfan A. Asangani John Scholler Khatuna Gabunia LOXHD1 Mei Ji OncoDaily Oncology Parker Institute for Cancer Immunotherapy Pouya Faridi Reyaz ur Rasool Rochelle Ayala Scientific Reports Tatiana Blanchard Terry C. C. Lim

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025